Scalper1 News
Top-rated drugmaker Akorn (AKRX) was down 20% in morning trading Monday as analysts weighed in on Friday evening’s news that it would again restate its 2014 earnings. Early Monday the company also announced a series of new executive appointments. The Street had assumed that the accounting problem, first revealed when the company filed for an extension of its 10-K report on March 2, had been resolved when Akorn issued a modest downward revision on Scalper1 News
Scalper1 News